 | | Vol. 14.45 – 1 December, 2022 |
| |
|
|
| Investigators reported that Large Tumor Suppressor 1 (LATS1), whose expression is often downregulated in human breast cancer, helped maintain luminal breast cancer cell identity by reducing the chromatin accessibility of genes that were characteristic of a “basal-like” state, preventing their spurious activation.
[Nature Communications] |
|  |
|
|
| PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Researchers revealed that selective hyper-activation of functional enhancer of zeste homolog 2 (EZH2) (H3K27me3) over non-catalytic EZH2 altered TNBC metastatic landscape and fostered its peritoneal metastasis, particularly splenic.
[Nature Communications] |
|
|
|
| By performing a high-throughput luciferase screening of 54 candidate miRNAs, the authors identified miR-182-3p as a specific and efficient post-transcriptional regulator of telomeric repeat-binding factor 2 (TRF2).
[EMBO Molecular Medicine] |
|
|
|
| Comparison of the orally bioavailable investigational elacestrant, versus fulvestrant, demonstrated both drugs impacted tumor growth of estrogen receptor (ER)+ patient-derived xenograft (PDX) models harboring several ESR1 mutations but that elacestrant was active after acquired resistance to fulvestrant.
[npj Breast Cancer] |
|
|
|
| By performing unbiased siRNA screening, researchers identified STAM-binding protein (STAMBP,) a JAMM metalloprotease in the deubiquitinase family, as a driver of human TNBC tumor growth.
[Experimental & Molecular Medicine] |
|
|
|
| Scientists exposed different breast cancer cell lines, including two TNBC ones, an human epidermal receptor 2 (HER2) enriched, and one cell line representative of the Luminal A molecular subtype, to short- or long-term copper-chelation by triethylenetetramine.
[Cellular Oncology] |
|
|
|
| Using the synthetic tumor microenvironment mimics, investigators showed that endothelial cell organization into vascular structures was breast cancer phenotype dependent, independent of ERα expression in epithelial cancer cells, and involved mesenchymal stromal cell-mediated Notch1 signaling.
[Communications Biology] |
|
|
|
| To identify chemical exposures that may increase breast cancer risk through estradiol (E2) or progesterone (P4) steroidogenesis, the authors developed a cheminformatics approach to identify structural features associated with increase in E2 and P4.
[Scientific Reports] |
|
|
|
| Based on the random forest, least absolute shrinkage and selection operator analysis, and multivariate Cox regression analysis, researchers constructed an interleukin signature. GSE22219, GSE25065, and GSE21653 were derived as validation sets.
[Scientific Reports] |
|
|
|
| Heparan sulfate chains were degraded in vitro as TNBC cells MDA-MB-231 and HCC1806 were treated with heparinase I and III. Subsequently, radioresistance was determined via colony formation assay after doses of 2, 4, and 6 Gy.
[Archives of Medical Research] |
|
|
|
Scientists briefly summarize the functions and categories of circular RNAs (circRNAs), their different roles in breast cancer, and recent research and therapeutic progress related to circRNAs.
[World Journal of Surgical Oncology] |
|  |
|
|
|
| Scientists briefly summarize the functions and categories of circular RNAs (circRNAs), their different roles in breast cancer, and recent research and therapeutic progress related to circRNAs.
[World Journal of Surgical Oncology] |
|
|
|
|
| PreciseDx announced a collaboration with the Laboratory of Pathology at Dordrecht, Netherlands. Through this agreement, the Laboratory of Pathology will study the performance of PreciseDx’s AI-driven Cancer Risk Stratification platform, confirming its accuracy of staging and role in the decision process.
[PreciseDx] |
|
|
|
|
| April 25 – 26, 2023
London, England, United Kingdom |
|
|
|
|
|
| | Nencki Institute of Experimental Biology, PAS – Warsaw, Poland |
|
|
|
| | Indiana University School of Medicine – Bloomington, Indiana, United States |
|
|
|
| | University of Miami – Miami, Florida, United States |
|
|
|
| | STEMCELL Technologies, Inc. – Boston, Massachusetts, United States |
|
|
|
| | Breast Cancer Research Foundation – New York, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
